CONFIRMED: Here’s Your Report!

How To Find Diamonds in the Rough Awareness Stocks ???? How To Find Diamonds in the Rough Consistent returns aren’t just nice to have…they’re a necessity. Yet, many folks struggle to beat the S&P 500. Ironically, they ignore the very thing that could provide them with uncorrelated returns- penny stocks. We know major stocks rise and fall together - the whole rising tide lifts all boats. So, the excess gains aren’t great even when you pick a winner. This is precisely why we focus on penny stocks. These cheaply priced equities live and die by their news cycle and the traders who follow the stock. But there’s one immensely powerful group whose influence can send a stock soaring… …which is why we’re constantly scouring our sources for the timeliest penny stocks promotions. That’s where we can find hidden gems that don’t just crush the market but do it on their own time. A market in freefall won’t slow down these profitable performers. However, the only way to get ahead is to stay on top of the feeds with the clout to pump these stocks. That’s why this week’s newsletter highlights three tickers garnering a whole lot of talk. Mainz Biomed (NASDAQ: MYNZ) Genetic testing plays a critical role in today’s healthcare marketplace. In the U.S. alone, the market size for this niche role sat at $4.38 billion in 2020. That’s expected to grow to $10.29 billion by 2027, an eye-popping 13% CAGR. Mainz Biomed’s flagship ColoAlert is a non-invasive, easy-to-use early detection test for colorectal cancer, a disease affecting 46,000 people in the U.S. annually and 1.93 million worldwide. Already marketed in the U.S., Mainz Biomed is currently operating a crucial FDA clinical study for regulatory approval. Globally, ColoAlert is approved and available in Europe and select international markets. Just last week, the company formed commercial partnerships with Marylebone Laboratory of England and Instituto de Microecologia of span, two leading independent laboratories, allowing the company to process tests in these local markets. All this comes after two prominent analyst calls: - Cantor Fitzgerald initiated coverage with an overweight recommendation with a $15 price target. - Jones Research initiated coverage with a buy rating with an $11 price target. - H.C. Wainwright initiated coverage with a buy rating with a $25 price target. Recent promoter activity listed the following as 10 catalysts for the stock: - Multiple analysts now bullish on the stock - H.C. Wainwright coverage - Cantor Fitzgerald coverage - Jones Research coverage - The company seeking FDA approval for ColoAlert - Mainz Biomed is in the same space as Exact Sciences Corporation (EXAS), which is up +700% in the last five years - The company could become a potential acquisition target - Stock is listed on the NASDAQ exchange, allowing for premarket trading - The company is led by a seasoned and experienced management team - Key appointed have been made to the board It’s worth noting that the analysts initiating coverage only major new developments. Everything else is either known or speculation. Nonetheless, there’s been a massive uptick in volume, with +282k shares trading last Wednesday, far above the 20,000 average. One promoter disclosed payments of $120,000 total, $20,000 of which is tied to their most recent promotion. Another disclosed payment of $14,500 for the most recent promotion. This is typical for lower-end promotional spends on a stock that’s been pushed previously. It remains to be seen whether we’ll see any follow-through but this is definitely one that could surprise us in the coming weeks. Actinium Pharmacetuticals Inc. (AMEX: ATNM) Cancer research is and will be a hot topic and a heavy investment until humanity conquers the disease. Global oncology spend hit $187 billion in 2021. So, any company that can take even a sliver of market share could be worth billions. Hitting the heart of the matter, Actinium Pharmaceuticals Inc.is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular-level precision to treat patients with high unmet needs. Like any other biotech and pharma company, ATNM lives and dies by its research and trial results. Promoters recently highlighted the company’s press release over the weekend that noted the following: “Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm.” [kZy25Qxt2sKLTP8m-wjRTaL5YPbGICqtbDVmB8xeY6K3KaAh4hM8BbDja-ieMHwoDQbJsONec_d81rnMVLbmOG65d1fEFxdusq6kx804Qa79RBXsMlpvdKlHff2rgxkUYP9Jm3Hm_qcjQ_CVnwsGZvw] In other words, the study showed the treatment was effective. The following timeline forecast was also provided by the company: [ZbHAWw6omJhWji2C3jxsZ7H9TsUEg7vdbJk5CjaF9HiArKDU4jzg5g7sYNAuBB3J2hYKt92U0TBHJ-Fw94f4dKZnBQ3qhNpsYze7GkzR76Iw1FHe0ksWM5ChOaNqkmnmvKXHRomTtYMHX98wPy7YAGc] It’s worth noting that the study included 153 patients, a fairly small sample size for a Phase 3 trial, but still statistically significant. This news was the crux of the promoters arguments in favor of the company. Promoters also noted HC Wainwright reiterated its ‘Buy” rating on February 7th, issuing a $53 price target, a whopping +250% from current prices. The other qualitative piece of news highlighted was the company’s recent research and development cooperative agreement with the National Cancer Institute (NCI) to “further enhance clinical and non-clinical development of Actimab-A for the treatment of Acute Myeloid Leukemia and other hematologic malignancies.” The NCI will sponsor and oversee clinical trials of Actimab-A, which is currently finishing phase one trials. Other catalysts cited include potential technical breakouts, all subjective at best. We did note that one firm promoting the stock has been paid $192,500 for its activities, of which $25,000 was related to the most recent promotion. The other major promoter highlighted a similar fee for its recent promotion. The stock carries a 25.5 million float with a market cap of just under $290 million. In early November, shares ran hard from $7.00 to just over $15, which coincided with prior promotional campaigns. So, if you ever wonder whether these promoters are worth following, all you have to do is look at their past performance. We'll be in touch soon, Awareness Stocks Team Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](